Influenza vaccination in patients with multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Public Health

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Influenza vaccination is recommended for individuals with chronic health conditions, but safety concerns exist in MS patients.

Purpose of the Study:

• To evaluate the safety and tolerability of influenza vaccination in patients with multiple sclerosis.

Main Methods:

• A cohort of 93 multiple sclerosis patients received 209 doses of influenza vaccine.
• Adverse events, including new lesions and allergic/toxic reactions, were monitored.

Main Results:

• Vaccination was well tolerated in 93% of patients.
• One patient developed a new lesion post-vaccination, but the relapse rate was low.
• Toxic and allergic reactions occurred in 7% and 0.5% of vaccinations, respectively, similar to the general population.

Conclusions:

• Influenza vaccination is safe and well-tolerated in multiple sclerosis patients.
• Vaccination does not appear to increase the risk of new lesions or relapses in MS.
• The safety profile is comparable to that observed in the general population.